LUNG: the cashflow

MyFinsight

For the quarter ending 2025-09-30, LUNG had $1,085K increase in cash & cash equivalents over the period. -$8,251K in free cash flow.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net loss	-13,957	-29,621
Stock-based compensation expense	5,166	11,826
Impairment of capitalized software development costs	0	0
Change in allowance for credit losses	0	0
Inventory write-down (recovery), net	72	-96
Depreciation and amortization expense	246	577
Amortization of debt discount and debt issuance costs	14	24
Net accretion of discounts on marketable securities	40	339
Non-cash lease expense	465	615
Accounts receivable	-1,410	1,941
Inventory	1,021	-1,066
Prepaid expenses and other current assets	913	-1,099
Other assets	-122	359
Accounts payable	121	2,645
Accrued liabilities	528	-2,364
Income taxes payable	-7	92
Lease liabilities	-381	-293
Deferred revenue	13	-61
Net cash used in operating activities	-8,162	-17,130
Purchases of investments	0	5,651
Maturities of investments	8,800	27,785
Purchases of property and equipment and internal software development costs	89	350
Net cash provided by investing activities	8,711	21,784
Repayment of credit agreement	1	48
Debt issuance cost	23	47
Proceeds from exercise of common stock options	5	138
Proceeds from issuance of common stock under the employee stock purchase plan	200	554
Net cash provided by financing activities	181	597
Effect of exchange rate changes on cash and cash equivalents	355	-688
Net increase (decrease) in cash, cash equivalents, and restricted cash	1,085	4,563
Cash and cash equivalents at beginning of period	71,162	-
Cash and cash equivalents at end of period	76,810	-

Unit: Thousand (K) dollars